NCT00149227View on ClinicalTrials.gov

Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)

PHASE4CompletedINTERVENTIONAL
Enrollment

3,031

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

January 31, 2009

Study Completion Date

January 31, 2009

Conditions
HypertensionIschemic Heart DiseaseCongestive Heart FailureStroke
Interventions
DRUG

Valsartan

Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.

DRUG

Non-ARB

'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs

Trial Locations (1)

602-8566

Kyoto Prefectural University of Medicine, Kyoto

All Listed Sponsors
lead

Kyoto Prefectural University of Medicine

OTHER

NCT00149227 - Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study) | Biotech Hunter | Biotech Hunter